Advances in diagnostic imaging such as X-ray, CT and ultrasound have created a major impact on reducing the necessity of invasive diagnostic procedures. Yet, several barriers and limitations in these technologies have failed to restrict the growth of biopsies carried out over the world. An invasive biopsy is a procedure of sampling tissue from the area that is expected to be cancerous or hiding a tumor. Biopsy devices are specialized needled devices that can extract tissue samples in order to run further medical tests. Today advanced and more accurate methods such as core needle biopsy (CNB) and vacuum-assisted biopsy (VAB) are being used besides fine-needle aspiration (FNA). The VAB is a market driving technology due to its greatest accuracy in diagnosing breast cancers. The devices are also priced higher and are thus creating maximum impact on the market. Previously there were very few devices that allowed minimally invasive procedure for analyzing tumor tissue sample and with the advancing technology, even low-risk patients can undergo the procedure in order to confirm the presence or absence of cancer without having to undergo the consumption of high value drugs and chemicals such as tumor seeking radiopharmaceuticals. The market for Biopsy Devices can be segmented into several applications and products types. The technology can be broadly classified into needled biopsy devices or biopsy guns, biopsy brushes, biopsy curettage devices, biopsy punches, biopsy forceps.
Although the term biopsy is today extended into mammograph devices, this report deals only with minimally invasive biopsy devices available on the market. The major techniques for biopsies are Fine Needle Biopsies that were most common, Core Needle Biopsies, Vacuum Assisted Biopsies and Open Surgical Biopsies. Major drivers for the biopsy devices market are rising incidence in cancer of lung, breast, liver, thyroid, prostate, cervical and uterine cancer among several others; aging population that is driving the growth of disease in several parts of the world; technological challenges faced by non-invasive and predictive tests for cancers. According to World Cancer Research Fund breast cancer is the most common type of cancer in women with approximately 1.4 million cases added each year. In 2012, WHO and Cancer Research U.K., presented facts that suggested lung cancer and breast cancer to be the most rampant types that led to 8.2 million deaths worldwide. With these numbers, SA-BRC forecasts very strong growth for all diagnostic tests and confirmatory tests such as biopsies in the forecast period.
For More Research Reports@ http://www.sa-brc.com/Medical-Devices/industry1
Image guided needled biopsies will further strengthen the growth as minimally invasive procedures become routine for confirmation tests. This is particularly true for developed regions such as North America and parts of Europe. Fine Needle Biopsy still forms the core part of diagnosis in developing countries and will require a few more years to gather momentum. Several companies are now looking forward to invest in emerging nations such as Brazil, China and India. The notable players in the market are Cardinal Health, PFM Medical, Kimberly Clark, Cook Medical, C.R Bard, AngioTech, Scanlan and Cadence among several others.
NOTE: This report is currently under research and will be made available to clients on request.